Summary & Overview
HCPCS A9597: PET Radiopharmaceutical for Tumor Identification, NOS
HCPCS Level II code A9597 denotes a PET radiopharmaceutical used for diagnostic tumor identification when no more specific radiotracer code applies. This code matters nationally as PET imaging with specialized radiopharmaceuticals plays a central role in oncology staging, treatment planning, and response assessment. Accurate coding for tracers that lack dedicated codes affects clinical documentation, claims processing, and consistent national reporting for advanced imaging.
Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how A9597 is used clinically, the typical sites of service where these diagnostic agents are administered, and practical implications for billing and claims processing. The publication outlines benchmarking considerations, common billing modifiers relevant to component reporting, and areas where policy updates or payer-specific coverage rules could affect claim adjudication. Where input data is missing, the summary notes the absence rather than inferring specifics.
This national-level briefing is intended for revenue cycle professionals, hospital and imaging center administrators, and policy analysts who need a clear, focused reference on the clinical purpose and billing context of HCPCS Level II code A9597.
Billing Code Overview
HCPCS Level II code A9597 describes a positron emission tomography (PET) radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified. This code represents a diagnostic imaging agent used in PET scans to identify and characterize tumors when another specific radiopharmaceutical code does not apply.
-
Service type: Diagnostic PET radiopharmaceutical administration for tumor identification
-
Typical site of service: Outpatient imaging centers, hospital-based imaging departments, and ambulatory diagnostic centers
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a history of a treated colorectal carcinoma presents with rising carcinoembryonic antigen (CEA) levels and equivocal findings on contrast-enhanced CT. The oncology team orders a tumor-targeted PET radiopharmaceutical study to localize possible recurrent or metastatic disease. The imaging appointment occurs in an outpatient nuclear medicine or PET/CT center. The workflow includes: pre-authorization and verification of indications, review of recent lab values and allergy history, patient preparation (fasting, hydration, medication instructions), radiopharmaceutical preparation and quality check by the radiopharmacy, intravenous administration of the PET radiotracer, an uptake/incubation period, patient positioning and CT localization, PET emission acquisition with concurrent or subsequent diagnostic CT as indicated, image reconstruction and attenuation correction, interpretation by a board-certified nuclear medicine physician or radiologist, and issuance of a signed diagnostic report. The study uses billing code A9597 for a diagnostic PET radiopharmaceutical for tumor identification not otherwise classified; the facility bills the technical component and the interpreting physician bills the professional component as applicable. Common sites of service include outpatient imaging centers, hospital outpatient departments, and ambulatory surgery centers that provide PET/CT services.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 |